Melanoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PD-1 55
• BRAF 18
• PD-L1 22
• MEK 7
• TP53 0
• CTLA-4 10
• MAPK 2
• NRAS 8
• STING 0
• STAT3 0
• PRAME 3
• AKT 0
• PI3K 0
• BAP1 2
• VEGF 4
• mTOR 0
• ERK 0
• LAG-3 2
• CTNNB1 0
• RAS 2
• CD40 0
• CDKN2A 3
• TNF 0
• YAP 0
• PTEN 1
• JAK 0
• KIT 3
• KRAS 1
• JNK 0
• PPAR 0
• TIGIT 0
• ALK 0
• B7-H3 3
• BCL-2 0
• EZH2 0
• HIF-1 0
• IL-15 1
• NF1 2
• NLRP3 0
• NRF2 0
• AMPK 0
• HSP90 0
• CD47 0
• MYC 0
• PKM2 0
• AXL 1
• COX-2 0
• EGFR 0
• GPX4 0
• HDAC 1
• IDH 1
• IL-17 1
• MET 1
• MMP-9 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• HER2 3
• IGF1R 0
• PSMA 3

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 3,285 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  NCT04318717· Washington University School of Medicine· Updated 6 Nov 2026

  “protocol amendment”Registry text, quoted unchanged. Source

• Withdrawn

  Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp

  NCT07803562· University of California, San Diego· Updated 6 Nov 2026

  “Lack of funding”Registry text, quoted unchanged. Source

• Suspended

  Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial

  NCT06673095· OHSU Knight Cancer Institute· Updated 20 Oct 2026

  “Pending coordinating center transition”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

  NCT05879822· Incyte Corporation· Updated 20 Oct 2026

  “This was a strategic business decision. There were no safety concerns contributing to this decision.”Registry text, quoted unchanged. Source

• Suspended

  CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases

  NCT05669352· Mayo Clinic· Updated 20 Oct 2026

  “transition to new institution”Registry text, quoted unchanged. Source

• Withdrawn

  Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

  NCT06365619· University of Utah· Updated 19 Oct 2026

  “Low Accrual”Registry text, quoted unchanged. Source

• Suspended

  The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)

  NCT04866810· National Cancer Institute (NCI)· Updated 19 Oct 2026

  “On hold pending planned interim analysis.”Registry text, quoted unchanged. Source

• Terminated

  A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

  NCT05529316· Agenus Inc.· Updated 19 Oct 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

  NCT06566092· Iovance Biotherapeutics, Inc.· Updated 16 Oct 2026

  “After reviewing the available safety and efficacy data to date, Iovance has made the decision to conclude all remaining participant visits.”Registry text, quoted unchanged. Source

• Withdrawn

  Digital Phenotyping of Psychological Distress in Skin Cancer Patients

  NCT07670403· West China Hospital· Updated 16 Oct 2026

  “poor accrual”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

  NCT04971499· April Salama, M.D.· Source

• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

  NCT06246916· Regeneron Pharmaceuticals· Source

• Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies

  NCT00923026· National Cancer Institute (NCI)· Source

• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

  NCT05155033· National Cancer Institute (NCI)· Source

• Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate 76K)

  2022-502354-14-00· Bristol-Myers Squibb Services Unlimited Company· Source

• Harvesting Cells for Experimental Cancer Treatments

  NCT00068003· National Cancer Institute (NCI)· Source

• Evaluation for NCI Surgery Branch Clinical Research Protocols

  NCT00001823· National Cancer Institute (NCI)· Source

• Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers

  NCT07815873· European Institute of Oncology· Source

• Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  NCT06418204· Wake Forest University Health Sciences· Source

• A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  NCT07492680· Bristol-Myers Squibb· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 51
• Organoids 8
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 21
• Gene Expression Profiling 116
• Sequence Analysis, RNA 9
• Whole Genome Sequencing 6
• Exome Sequencing 7
• Proteomics 46
• Metabolomics 20
• Mass Spectrometry 9
• Flow Cytometry 65
• Immunohistochemistry 106
• Liquid Biopsy 12
• Circulating Tumor DNA 37
• Xenograft Model Antitumor Assays 120
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 56
• Machine Learning 47
• Deep Learning 44
• Cohort Studies 77
• Genome-Wide Association Study 22

• Capture and Isolation of Circulating Melanoma Cells Using Photoacoustic Flowmetry.

  Methods Mol Biol, Jan 2027

• Imaging and Analysis of Melanoma-Secreted Extracellular Vesicles in Tumor-Draining Lymph Nodes.

  Methods Mol Biol, Jan 2027

• A Flow Cytometric Assay for Investigating Melanoma Cell Adhesion to Lymphatic Endothelial Cells.

  Methods Mol Biol, Jan 2027

• A Fluorescence-Based Assay for Measuring Glucose Uptake in Living Melanoma Cells.

  Methods Mol Biol, Jan 2027

• Evaluating Melanoma Cell Migration/Invasion in Transwell Assays by Flow Cytometry.

  Methods Mol Biol, Jan 2027

• Anti-tumour activity of canine activated T-cells and cytokine-induced killer cells against canine malignant melanoma in vitro.

  Vet J, Jul 2026

• Redox index and capacity analysis (RICA) reveals NAD biology changes in T cell responses in vitro and ex vivo.

  J Immunol, Apr 2026

• LNP-Delivered CAR-mRNA Enables in Vivo CAR-Macrophage Production for TYRP1-Targeted Therapy of Choroidal Melanoma.

  Curr Eye Res, Apr 2026

• Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis.

  Eur J Surg Oncol, Jan 2026

• PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells.

  Nat Commun, Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.